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Dr. Gunnar Mair 
Current Models of Ovarian Cancer 
ABSTRACT 
 Ovarian cancer has proved to be one of the most difficult cancers to treat. It is often 
diagnosed in the late stages. When it is detected early, the 5-year survival rate is 93%. 
However, it is only detected early 15% of the time. For this reason, there is an emphasis on 
finding better tumor markers that can identify cancerous cells early. Ovarian cancers come 
from 3 different cell types. There are a variety of cancer subtypes from each type of cell. A one-
size fits all treatment method isn’t feasible with so much variation. Models of ovarian cancer 
help understand the pathway of cancer development, find tumor markers for early detection, 
improve imagining techniques, and test drug therapies. Current models include transgenic 
mice, xenograft mice, chick chorioallantoic membrane, the laying hen, and 3-D human tissue 
cultures. Unfortunately, there are plenty of flaws with these models that researchers are trying 
to overcome. Determining which model is the best representation of human ovarian cancer is 
crucial for making progress in treating ovarian cancer. In this review I will provide an overview 
of current models for ovarian cancer. I will be looking at current research done with these 
models to explore their benefits and disadvantages. 
INTRODUCTION 
 In 2018, roughly 14, 070 women will die from ovarian cancer and 22,240 new cases will 
be diagnosed [1].  Women over 63 make up half of the cases. It is the 5th leading cause of cancer 
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related deaths in women [2]. The odds of a woman dying from ovarian cancer are 1 in 108 [2]. 
The symptoms of ovarian cancer include pelvic and abdominal pain, bloating, nausea, vomiting, 
indigestion, trouble eating, feeling full quickly, urinary urgency and frequency, fatigue, back 
pain, pain during sex, changes in periods, abdominal swelling with weight loss, and a change in 
bowel habits [3-4]. Unfortunately, early stages of ovarian cancer are usually asymptomatic and 
later stage symptoms are non-specific [5]. As a result, ovarian cancer is not typically detected in 
the early stages which leads to low survival rates. When it is detected early, before metastasis, 
patients have a 5-year survival rate of 93% [3]. Unfortunately, only 15% of ovarian cancer is 
detected in the early stages. The 5-year survival rate for stage 3 epithelial ovarian cancer ranges 
from 63%-28% depending on the sub classification. Stage IV epithelial ovarian cancer has a 19% 
5-year survival rate [4]. 
 Ovarian cancers are given a stage after diagnosis. Stages describe how far the cancer has 
spread with stage I indicating the least amount of spreading. Stage IV is the maximum. There 
are 3 factors used to stage the cancer in both the International Federation of Gynecology and 
Obstetrics and the American Joint Committee on Cancer TNM staging system. The factors 
include the extent of spreading (T), spreading to the lymph nodes (N), and metastasis to distant 
sites (M). Staging cancers help with talking about survival statistics as well as determining the 
severity and the best way to treat it. Most statistics are given in 5-year survival rate. These 
statistics look at how many people are still alive 5-years after treatment based on the stage the 
cancer was in when the patient was first diagnosed. They do account for new, improved 
treatment methods. They do not include cancers that come back or spread. They also do not 
adjust for many other factors such as age, overall health, and effectiveness of the treatment [4]. 
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Cell-Type Specific Ovarian Tumors 
 There are 3 cells types in the ovaries and they develop into different types of tumors. 
The epithelial tumors are called carcinomas. They are the most common making up 85%-90% of 
malignant tumors. There are 4 main types [3]. These are differentiated by the same genes that 
are responsible for epithelial differentiation during embryonic development [6]. The serous 
carcinomas make up 52% of epithelial carcinomas. The serous membranes these carcinomas 
resemble are a type of epithelial tissue covers organs in closed cavities of the body. It is covered 
by a thin layer of serous fluid secreted by the epithelium [7]. The other main types are clear 
cell, mucinous, and endometroid carcinoma. Together they only make up 22% of epithelial 
carcinomas. They also are considered low-grade—grade 1—carcinomas because they look more 
like normal tissue. Grades are used to describe how close the cancerous tissue looks to non-
cancerous tissue with 1 being the closest to non-cancerous tissue. Patients with low-grade 
carcinomas have better prognosis. While these tumors grow slowly, they cause fewer 
symptoms and typically do not respond well to chemotherapy.  Serous carcinomas can be low-
grade or high-grade—grade 3—carcinomas. High-grade carcinomas look less like normal tissue 
and usually have a worse prognosis for patents. While they grow and spread sooner, they seem 
to response better to chemotherapy [3].  
 The second cell type in the ovary are the germ cells. These come from the ova in 
females. They make up less than 2% of ovarian cancers and are typically benign. When they are 
cancerous, 5-year survival is at 90%. The most common subtypes are teratomas, 
dysgerminomas, endodermal sinus tumors, and choriocarcinomas.  The most common cancer 
stemming from the germ cells are called dysgerminomas. They predominantly affect women in 
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their teens and twenties. However, they don’t grow or spread rapidly. If they are removed 
before they spread beyond the ovary, 75% of patients do not need further treatment. In cases 
where the tumor has spread, 90% of patients can cure or manage the cancer with a surgery, 
radiation, and/or chemotherapy. Teratomas look like the 3 layers of the developing embryo 
when viewed under the microscope. There is a benign tumor called a mature teratoma that 
predominantly affects women of reproductive age. Immature teratomas are cancerous and 
predominantly affect women under 18. When they are still grade 1 and have not spread to 
other organs, they are treated by surgery. Grade 2 and 3 that have spread past the ovaries are 
commonly treated with a combination of surgery and chemotherapy. Endodermal sinus tumors 
and choriocarcinomas affect girls and young women. Although they tend to grow and spread 
rapidly, they are very sensitive to chemotherapy. Choriocarcinomas can start in the placenta or 
the ovaries. The ones that start in the placenta are more common and typically respond better 
to chemotherapy [3]. 
 The third cell type of the ovary is the stroma. Tumors of these cells only make up 1% of 
ovarian cancers. Over half of them develop in women 50 years or older. However, 5% do 
develop in young girls. While they are less common, they do have better defined symptoms 
than the other ovarian cancers. They can cause abnormal vaginal bleeding due to the 
production of female hormones. They can start menstrual periods and breast development to 
happen before puberty in young girls. Conversely, these cells can also release male hormones 
that stop periods and cause facial and body hair to grow. These tumors can also bleed which 
can cause sudden, severe abdominal pain. The most common type are granulosa cell tumors 
which are malignant. The granulosa-theca tumors and Sertoli-Leydig cell tumors are also 
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cancerous stromal tumors. They are usually found in the early stages. Most than 75% of 
patients survive long-term [3]. 
Causes of Ovarian Cancers 
 For most ovarian cancers, the cause is still unknown. There are inherited genetic 
mutations like BRCA1, BRCA2, PTEN, STK11, and MUTYH that increase the risk of developing 
ovarian cancer. Risk factors for germ cell and stromal tumors of the ovaries are not well known. 
However, from the known risk factors for epithelial ovarian cancers, there are several theories 
about the causes. There seems to be reduced risk when the woman ovulates less. Irrespective 
whether that’s due to pregnancy or birth control with hormonal contraceptives. The fact that 
tubal ligation and hysterectomy lowers the risk has led to a theory that cancer-causing 
substances travel to the ovaries from the vagina. There is another theory that androgens—male 
hormones—can cause ovarian cancer.  Tests for acquired genetic mutations like the TP53 
tumor suppressor gene or the HER2 oncogene may also predict the outcome for the patient 
indicating that these mutations are key in pathogenesis [8].  
Ovarian Cancer Detection 
 During regular health exams, ovarian cancer is hard to catch. Pelvic exams check for the 
size, shape, and consistency of the ovaries and uterus but often miss early ovarian tumors. 
Advanced stages of ovarian cancer may show up on a pap test used to test for cervical cancer, 
but this is extremely rare. In combination with pelvic exams, transvaginal ultrasounds and 
cancer antigen protein (CA-125) blood tests may be given to screen for ovarian cancer. 
Unfortunately, both of these methods are flawed. Transvaginal ultrasounds help find masses in 
the ovaries, but most of those found are benign. The CA-125 blood test measures the amount 
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of CA-125 which is usually elevated in women with ovarian cancer. It is commonly used to test if 
treatment is working in women known to have ovarian cancer because successful treatment 
will lower it. Unfortunately, it is not always elevated in women with ovarian cancer. Levels can 
also rise from endometriosis and pelvic inflammatory disease. Screening is not recommended 
for women with average risk and no symptoms. Some germ cell cancers release human 
gonadotropin and alpha-fetoprotein which can be used to see if treatment is working or if the 
cancer has returned, but these are not recommended for screening. Other imaging tests may 
be used to determine if a pelvic mass is present and if it has metastasized. These imaging tests 
include: ultrasound, CT scans, barium enema x-ray, MRI, x-ray, and PET scans. Laparoscopy and 
Colonoscopy allow for biopsies to be done. Biopsies take a remove a piece of tissue for study in 
the lab. In a procedure called paracentesis, a syringe retrieves fluid from the abdominal cavity if 
the patient has ascites. The fluid can be tested for cancerous cells. Biopsies and paracentesis 
are the only way to know confirm a growth is cancerous. There are currently no other reliable 
screening tests although many are being heavily researched. Finding a reliable screening test to 
detect ovarian cancer early may be pivotal in preventing deaths [4]. 
Ovarian Cancer Treatment 
 There are a variety of treatments available.  Local treatments that affect just the tumor 
and not the rest of the body include surgery and radiation therapy. Systemic treatments that 
affect the whole body include chemotherapy, hormone therapy, and targeted therapy. Surgery 
removing the uterus, both, fallopian tubes, the ovaries, and omentum is usually done when the 
patient has epithelial ovarian cancer. The tissue is then tested in order to accurately classify the 
cancer stage. If the patient is in early enough stages and is of childbearing age, they might not 
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have both ovaries and the uterus removed. It depends on the spreading of the cancer as well as 
the general health of the patient.  When the cancer has already spread to the abdomen, the 
surgeon will try to remove as much of the tumor as possible. This is called debulking. Optimal 
debulking removes all visible cancerous tissue and leaves no tumors larger than a half-inch. 
Optimal debulking greatly improves prognosis for the patient. Germ cell and stromal cell 
cancers also lead to the removal of the uterus, fallopian tubes, and ovaries. However, keeping 
non-cancerous tissue until the patient has finished having children is more common with these 
types of cancer. 
 Chemotherapy can be useful after surgery to kill off any cancer cells left behind or 
metastasized. It can be used before surgery to shrink large tumors, making surgery easier. 
Chemotherapies are usually given through IV, intraperitoneal catheter, or orally.  A combination 
of two different types of drugs are typically used. One is called a platinum compound and the 
other is called a taxane [9]. Platinum compounds covalently bind to DNA which ultimately 
results in apoptosis [10]. Taxanes bind microtubules so androgen receptors cannot move to the 
nucleus [11]. There are also several other chemotherapy drugs that are not platinum 
compounds or taxanes that may be helpful in treatment. Chemotherapy is typically given every 
3-4 weeks for 3-6 cycles depending on the stage and type of the cancer. Cycles involve regular 
administration of the drug and then a period of rest. If the chemotherapy seems to work well 
and the cancer stays away for 6 to 12 months, the same chemotherapy regiment is 
recommended.  If the patient is in stage III and the tumors have been optimally debunked, an 
intraperitoneal chemotherapy treatment may be used in combination with systematic 
chemotherapy. This is given through a catheter that has been placed in the abdominal cavity. 
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Although it may increase life-span, the chemotherapy side effects of nausea, vomiting, and 
abdominal pain can be more severe. For germ cell tumors, a combination of drugs called BEP 
are used. This includes bleomycin, etoposide, and cisplatin. Dysgerminoma may be treated with 
carboplatin and etoposide because these tumors are more sensitive to chemotherapy and this 
combination is less toxic. If the tumor doesn’t response, the patient may be given a high dose 
chemotherapy treatment or an assortment of different drugs. Stromal tumors are not usually 
treated with chemotherapy [9]. 
 Temporary side effects of chemotherapy include nausea, vomiting, loss of appetite, loss 
of hair, hand and foot rashes, mouth sores, increased risk of infection, easy bruising and 
bleeding, and fatigue. These usually go away after treatment is over. Unfortunately, certain 
drugs have long-term or permanent side effects. Cisplatin can cause kidney damage. Cisplatin 
and taxanes can cause nerve damage. Cisplatin specifically can damage nerves going to the ears 
which leads to hearing loss. Ifosfamide can cause irritation and bleeding of the bladder lining. 
Chemo can cause early menopause and infertility. Sometimes certain chemotherapies can 
permanently damage bone marrow. This may lead to second cancer of the blood [9].  
 Targeted therapies attack cancer cells while inflicting little damage to the normal tissue. 
Angiogenesis inhibitors such as bevacizumab attach to and inhibit a protein called VEGF. VEGF 
signals new blood vessels to form. Without new blood vessels to provide nutrients, the cancer’s 
growth is slowed or stopped. This drug works better in combination with chemotherapy, but it 
doesn’t seem to help increase the patient’s life-span and has several side-effects. Common side 
effects include high blood pressure, tiredness, bleeding, low white blood cell counts, 
headaches, mouth sores, loss of appetite, and diarrhea. More serious side effects are rare but 
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include blood clots, severe bleeding, slow wound healing, holes in the colon, and abnormal 
connections between the bowel and skin or bladder. PARP inhibitors block the PARP enzyme 
that helps repair damaged DNA. Since the tumor cells cannot repair the damaged DNA, these 
cells usually die. Side effects include nausea, vomiting, diarrhea, fatigue, loss of appetite, taste 
changes, low red blood cell counts, belly pain, and muscle and joint pain. Like chemotherapy, 
these drugs may lead to blood cancers due to bone marrow damage [9]. People with BRCA 1 or 
BRCA 2 mutations may benefit from certain PARP inhibitors [4] like olaparib, rucaparib, and 
niraparib. Niraparib is also used to treat recurrent ovarian cancer if chemotherapy is not 
successful. A small portion of women with ovarian cancer have BRCA 1 and BRCA 2 mutations 
[9]. Genetic counseling is important to determine your risk as well as other family member’s 
risk. There are over 1,000 known BRCA mutations [4]. 
  Primary peritoneal carcinoma (PPC) is closely related to epithelial ovarian cancer. It 
looks the same as epithelial ovarian cancer that has metastasized in surgery. It also produces 
similar symptoms and elevates a tumor marker called CA-125 like ovarian cancer. PPC seems to 
start in cells lining the fallopian tubes and spreads along the surface of the pelvis and abdomen 
like ovarian cancer. For this reason, it can be difficult to determine exactly where the cancer 
started first [3]. 
 The methods of studying cancer have evolved with new technologies. Ovarian cancer 
models have move way past the days of inducing tumors with carcinogens after it was shown 
that this is not a relevant model [12, 13]. More relevant models have been developed over 
time. This paper will explore the current animal models as well as human cell culture models. 
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Each model has benefits and drawbacks. Hopefully improvements to these models will result in 
better treatment and earlier detection of ovarian cancer.  
GENETICALLY ENGINEERED MOUSE MODEL 
 High-grade serous ovarian cancers (HGSCs) are responsible for 70% of all deaths due to 
ovarian cancer. In the past few years, it has been proposed that the fallopian tubes may be the 
origin for this subset of ovarian cancer [14]. Development of a mouse model of HGSCs that 
would mimic the early alterations and disease progression by focusing on lesions in the 
fallopian tubes has been at the heart of many research studies trying to identify whether HGSCs 
can originate from this location [15]. Genetically engineered mouse models using Cre 
recombinase are popular methods for constructing human disease models including ovarian 
cancer.  
 Two examples include the Dicer-Pten and Pax8-Cre derived models. The Dicer-Pten was 
created by using an anti-Mullerian hormone receptor type 2-directed Cre recombinase to knock 
out DICER and PTEN. [14]. Anti- Mullerian hormone receptor type 2 is expressed in ovarian 
tissue [16] so this recombination event was not limited to the fallopian tubes. Dicer is an RNase 
III that is crucial in converting pre-miRNA to miRNA. Pten is a tumor suppressor that inhibits the 
PI3k pathway [14]. The Pax8-Cre model uses a PAX8 promoter to control the expression of Cre 
recombinase. Pax8 is a transcription factor for fallopian tube secretory cells and appears to be 
absent from ovarian surface epithelium. This was confirmed by performing -galactosidase 
stains on the organs from the first generation of Pax8-Cre mice crossed with Gt(ROSA) 
26Sortm1sor that have a loxP-Stop-loxP LacZ transgene. The fallopian tubes had the highest LacZ 
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staining pattern. The uterus had some, but the ovaries had none [15]. Knowing which cells gene 
inactivation happens in allows for testing of the hypothesis that alteration in the fallopian 
epithelium can cause ovarian cancer. 
 While Dicer-Pten was used to create one double knock-out model [14], the Pax8-Cre 
created five distinct models. Murine cohorts were created by using Pax8-Cre mice crossed with 
mice containing different loxP flanked genes as well as mutations. Mutants or knock-outs of the 
four tumor suppressors genes BRCA1, BRCA2, PTEN, and TP53 were used in different 
combinations to develop the five models [15]. BRCA1 and BRCA2 code for different proteins 
that help repair DNA damage [17, 18]. PTEN codes for an enzyme that is part of the stop 
replication signaling. This signaling induces apoptosis [19]. TP53 codes for the tumor protein 
p53. This protein binds directly to damaged DNA. The protein can signal DNA repair 
mechanisms or signal the cell to undergo apoptosis [20]. Mutations in P53 are ubiquitous in 
HGSCs [21]. However, in the Pax8-Cre mice with wildtype PTEN and altered BRCA2 and TP53 did 
not develop tumors as quickly or as frequently as the other mutations. This suggests that BRCA2 
and TP53 inactivation are not enough to initiate tumor development and progression. [15] 
 The highest incidence of serous tubal intraepithelial carcinomas (STIC) and fallopian 
tube transformation occurred in mice with an inactivated BRCA1, mutant TP53, and an 
inactivated PTEN as well as mice with BRCA2, mutant TP53, and inactivated PTEN. The fallopian 
tube transformations were characterized by secretory cell proliferation, loss of polarity, cellular 




 In both mice models, removal of the fallopian tubes prevented the development of 
HGSCs, but removal of the ovaries did not [14, 15]. Since the Dicer-Pten promoter was not cell 
type specific, it’s not certain which type of fallopian tube cells the cancers originated in. 
Analysis of the fallopian tubes in earlier stages suggested fallopian stromal cells may be the 
origin. In the double-knock out of Dicer-Pten, 100% of the mice develop serous carcinomas in 
the fallopian tubes that spread to the ovaries. The tumors then metastasize to the abdominal 
cavity much like HGSCs in humans. The histology and upregulation of genes in the double 
knock-outs closely resembled human serous carcinomas [14]. 
 In the Pax8-Cre models, the cohort’s ability to develop STICs and fallopian tube 
transformations did not always correlate with the ability to metastasize. Although all the mice 
with inactive BRCA1, mutant TP53, and inactive PTEN develop STICs and fallopian tube 
transformations, only a fourth of the mice showed ovarian as well as peritoneal metastasis. 
When the carcinomas did metastasize, it was consistent with the pattern HGSC spread in 
humans. Immunohistochemical analyses showed that many of the tumor markers in mice 
mimicked human HGSCs and STICs. In addition, HGSC biomarkers and copy number alterations 
to human HGSC and found they correlated [15]. 
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 As shown in Figure 1, the Dicer-Pten mice develops tumors in the fallopian tubes [14]. 
However, In the Pax8-Cre mice, the fallopian tubes did not develop tumors that are visible from 
a gross inspection. This can be seen in Figure 2. It is often noted in human HGSCs cases that the 
fallopian tubes lack visible tumors [15]. Fallopian tube cancer itself if rare, but similar to 
epithelial ovarian cancer [3]. 
 
XENOGRAFTED MICE MODEL 
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 Xenografts can be done with fresh cells or cell lines [22, 23]. Xenografts can be 
transplanted into the subcutaneous, intraperitoneal, subrenal capsule, and orthotopic tissue 
[24]. However, there is some debate about the orthotopic model.  The orthotopic model 
transplants tumor cells directly into the ovaries. Bioluminescent images from an orthotopic 
model can be seen in Figure 3 [24]. In mice, bursa membrane surrounds the ovaries and creates 
a unique microenvironment. It provides a barrier to the peritoneal cavity that may impair tumor 
development [25]. On the other hand, this unique microenvironment may be more like the 
primary tumor’s microenvironment than other transplant areas [24, 26]. Other injection sites 
may induce compensatory mechanisms. In intraperitoneal transplants of fresh patient tumors 
new murine stroma developed that may be imitating the primary tumor’s microenvironment 
[22].  
 
 By genomic characterization cell lines versus human ovarian cancer tissue, it was found 
that the most appropriate cell lines to model high-grade serous carcinomas were the least used 
in laboratories [23]. Although fresh tumor grafts allow for the best representation of the 
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primary cancer. The tumor tissue can be mixed with McCoy’s media was injected 
intraperitoneally in female SCID mice [22]. SCID mice are mice that cannot produce T, B, and NK 
immune cells. Another popular immunocompromised mouse used in xenografts are the nude 
mice. These mice lack a thymus can cannot produce T cells [26].  SCID have the tendency to 
develop spontaneous lymphomas so the tissue type of the tumors must be tested. The mixture 
of tumor and McCoy’s media leads to an engraftment rate of 74%. Serous, carcinosarcoma, and 
transitional tumor types can all engrafted. It is important to note that patients whose tumors 
did engraft successfully had lower overall survival than those that did not [22] indicating that 
there is a bias towards more aggressive cancer. The fresh tumor grafts are microscopically 
similar to the primary tumors. Glandular characteristics of adenocarcinoma and the 
proliferation index were intact in the tumor grafts. Testing for pan-cytokeratin expression which 
confirmed that the tumors are from epithelial tissue. Unfortunately, cells with leukocyte 
common antigen (CD45) from primary tumors do not coheterotransplant often [22].  
 The fresh tumor grafts show overlap between the genetic changes in the patient and the 
tumor graft. However, the levels of the tumor marker CA125 were only elevated high enough to 
detect in 3 models and they were not highly elevated unlike the patients [22]. Patient-derived 
xenografts are good at predicting how well anticancer therapies work (Pompili). Tumor grafts 
from platinum sensitive parent tumors are also sensitive to platinum. If treatment with 
carboplatin/paclitaxel that works on the patient, it also works on the tumor grafts [22]. Ideally, 
they could be used to test patient treatment methods before administering them to the patient 
[26]. There is also the possibility of using them in place of patient tissue for before and after 
treatment comparisons. This would eliminate the need for invasive procedures on patients to 
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collect more tissue. However, this method is not perfect and may prevent patients from getting 
all possible treatment methods if their tumor grafts do not respond well to the treatment [22]. 
Another drawback is that some patient derived xenografts are unable to metastasize. Until the 
method is perfected, the tumor grafts may serve as an ideal drug testing method or help with 
the discovery of new biomarkers [22] 
CAM 
 The chick chorioallantoic membrane (CAM) model uses fertilized chicken eggs which is 
much less expensive than immune compromised mice. They also require less animal oversight. 
The methodology involves human cancer cells into the CAM through a small window in the egg 
shell. By using OV8GFP—which is a human ovarian cancer cell like that expresses green 
fluorescent protein—tumor formation can be monitored through the window in the egg shell. 
When compared to slides of the human tumor, the tumors grown in the CAM closely resembled 
the original tumor. Histopathological tests showed the growth of an extracellular matrix as well 
as stromal cells. This model can also grow tumors from human tissue transplants [27].   
 In order to show the CAM model could demonstrate cell invasion, in vitro assays were 
performed using the OVCAR-3, SKOV-3, and OV-90 ovarian cancer cell lines for comparison. The 
OV-90 proved to be the most invasive. These cells migrated to a chemo attractant the fastest 
while going through 12 m pores in a Geltrex extracellular matrix. Ex ovo methods were not 
effective with a 10% rate of survival so this method was discarded. However, in ovo had much 
better results with a 70% survival rate. The in ovo test were done by creating a small window in 
the shell on the third day of embryo development which allows the CAM layer to detach from 
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the shell. 900,000 ovarian cancer cells were mixed with Matrigel and grafted on top of the CAM 
on day 11. On day 14, the ectoderm and the mesoderm were put through cytokeratin 
immunohistochemistry to assess the invasion of the cells from the ectoderm into the 
mesoderm. The results are shown in Figure 4. OVCAR-3 damaged the ectoderm more than the 
mesoderm. SKOV-3 damaged the mesoderm more than the ectoderm. The OV-90 cells invaded 
the mesoderm and destroyed the ectoderm. These results were consistent with in vitro assays. 
A neutralizing antibody was mixed with the Matrigel and OV-90 cells compared to a control 
anti-mouse IgG inhibited the OV-90 cells from invading the mesoderm [28]. This demonstrates 
how easy it is to test a new substance in the CAM model. 
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 Biodegradable PMO nanoparticles suspected to preferentially deliver drugs to the tumor 
were also tested in the CAM model. These nanoparticles were loaded with the chemotherapy 
drug doxorubicin. Doxorubicin damages DNA and induces apoptosis. These nanoparticles were 
injected intravenously once a tumor had been established. The cell death could be monitored 
from the window in the shell by bright field and green fluorescence using a fluorescent 
stereomicroscope. The organs of the fetal chicken were examined 3 days after injection. These 
were compared to eggs that had received no drug and eggs that had been given doxorubicin 
that was not bound to the nanoparticles. All of the eggs given nanoparticle bound doxorubicin 
survived the three days after injection and their organs appeared normal upon post-mortem 
examination. The eggs given 200 g of unbound doxorubicin did not survive, and their organs 
showed severe damage [27]. This studied showed how easily the toxicity of a drug could be 
monitored by using the fetal chicken in the CAM model.  
THE LAYING HEN MODEL 
 The laying hen has been used as a model of ovarian cancer due to the fact that they 
develop spontaneous ovarian cancers. In 4-year-old hens, 40% develop spontaneous ovarian 
cancers [30]. It could therefore be useful for testing new treatments [29]. Primary ovarian 
carcinomas from 2-year old hens were staged using the International Federation of Gynecology 
and Obstetrics Staging Systems for Ovarian Cancer in Humans as a reference. The tumor types 
were examined under light microscopy and classified by the WHO criteria for human ovarian 
cancers.  Like humans, the hens developed serous, endometrioid, mucinous, clear cell, or mixed 
cell type carcinomas in their ovaries. All 4 stages of ovarian cancer were present. However, 
hens only have one functioning ovary so contra-lateral criteria used in human staging did not 
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apply. An illustration comparing the productive tracts of humans and laying hens is in Figure 5 
[39].  
 Like humans, the hens also developed profuse ascites in some cases of advanced stage 
ovarian cancer. Precursor lesions were also present in the hens much like humans [29]. The hen 
carcinomas are similar to human ovarian cancers in their expression of tumor markers such as 
cytokeratin, epidermal growth factor receptor, Tag 72, proliferating cell nuclear antigen, TGF-a, 
E-cadherin, and CA125 [31-33]. Immune cells levels are increased in hens with ovarian cancer 
much like human cancers. The initiation events in models where ovarian cancer is induced are 
difficult to attribute to spontaneous cancers [34]. For this reason, hens serve as good model for 
improving imagining techniques. 3-year old hens with no abnormalities on the initial ultrasound 
were monitored daily for signs of abnormal ovarian function. They were given a gray scale 
ultrasound and a Doppler ultrasonography at 15, 30, and 45 weeks. Color Doppler imaging was 
used to identify vessels. The flow velocity waveform was measured to get an idea of blood flow. 
This was used to mark which hens seem to have tumor-associated neoangiogenesis. After 45 
weeks, the hens were euthanized, and the ovaries examined. Out of 15 hens, 9 had ovarian 
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tumor-associated neoangiogenesis were detected by Doppler ultrasonography before they 
were visible on gray scale ultrasonography. 3 had microscopic tumor lesions that had not been 
detected by either ultrasonography method. The other 3 were normal on the ultrasonography 
and normal in post-mortem analysis [35]. Although the hen may be useful in many studies, it 
takes at least 2 years for hens to develop tumors [29]. Hens also require more space than 
mouse models [36]. These are two contributing factors to the laying hen model being less 
popular.   
HUMAN TISSUE MODEL 
 The use of 3-D human tissue models would allow the use of human cells to be tested for 
drug interaction while maintaining their microenvironments. 3-D tissue models are closer to in 
vivo disease than monolayers cultures. Spheroids of epithelial ovarian cancer cell lines were 
created in hanging droplets [37]. Spheroids are sphere-shaped aggregates of cells [38]. An 
example of a spheroid is shown in Figure 6. To test cell viability, spheroid cultures were used to 
create xenografted mice. Highly vascularized and intraperitoneal tumors with hemorrhagic 
ascites formed in the same way monolayer xenografts do. The spheroids showed similar 
morphology to one another indicating they are highly reproducible. They can also be fixed and 
embedded in histogel for cross-sectioning.  
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 While the spheroids did not develop hypoxic or necrotic cores like some do, they were 
admittedly cultured for only a short time and remained small enough during that time that 
there was no need for angiogenesis to maintain nutrient absorption throughout the cells [37]. 
Since hypoxic conditions have been such a problem in spheroid studies, specialized culture 
equipment and synthetic coats have been developed to prevent this [38]. This spheroid model 
showed tumor gene expression patterns to in vivo models that are not present in monolayers. 
With some improvements, it may replace in vivo modeling [37]. 
CONCLUSION 
 As technology improves, so do the models of ovarian cancer. Transgenic mice have so 
much potential to unlock the mysteries ovarian cancer. Pax8-Cre mice allowed for multiple 
gene interactions to be studied. This provided evidence that mutation of PTEN is essential for 
developing HGSCs [15]. Although getting 100% tumor formation is appealing, the Dicer-Pten 
mice may prove to be a poor representation of all HGSCs [14]. As mentioned earlier, the 
fallopian tubes in the Dicer-Pten developed tumors before spreading to the ovaries which is not 
 22 
common in cases of human ovarian cancer [15]. The Pax8-Cre model has also received some 
criticism for not being able to develop ascites [21]. The fact that both studies were able to show 
their mice developed tumors resembling human HGSCs brings into question how to ensure that 
the model being used is the best one and which tests are the most crucial for making this 
determination. 
 While the laying hen model is able to form spontaneous tumors, it is often overlooked 
as an animal model. Even though hens produce tumors using the same cells types as humans, 
their reproductive anatomy is different [29]. While it may be useful for testing new drugs and 
risk factors, only 40% of laying hens develop tumors after 4 years [29]. The wait time necessary 
to use these animals and the cost of housing and care may not be worth it when there are on-
going improvements to other cancer models. 
 The xenograft model has a lot of potential for testing drug-therapies for individual 
patients. However, it is quite costly and has about the same rate of successful transplantation 
as the CAM model [22, 28]. The CAM and 3-D tumor graft models are both cheaper than 
xenografted mice and have similar capabilities. The CAM model can grow fresh tissue from 
patients just as well as a xenograft [22, 28]. The 3-D cell culture model is still new and might 
need some time to catch on. The ability to use human cells in vitro with no difference to in vivo 
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